Abstract: A therapeutic agent carrier for treating a defect in a bone is disclosed and can include a body that can be configured to approximate a portion of the bone. Further, the therapeutic agent carrier can include a plurality of grooves formed along the body. Each groove can correspond to an incremental length of the body. The therapeutic agent carrier can also include a plurality of dosage stamps along the body and each of the plurality of dosage stamps is adjacent to a corresponding to groove.

Abstract: An intramedullary drug delivery device is disclosed and can be inserted within a bone canal of a bone. The intramedullary drug delivery device can include a housing. A drug delivery region can be established along the housing. Also, the drug delivery region can be configured to substantially span a fracture within the bone.

Abstract: A bone cutting template is disclosed and can include a body. A plurality of grooves can be formed along the body and each groove can correspond to an incremental length of the body. The bone cutting template can include a plurality of length stamps along the body. Each of the plurality of length stamps can be adjacent to a corresponding groove.

Abstract: Systems, methods, and carriers for percutaneous delivery of growth factors to treat osteonecrosis in the hip and other locations are disclosed. A rolled carrier comprising a biphasic ceramic rolled by a collagen sponge, and carrying a growth factor, are inserted via a delivery tube or cannula into a pre-formed hole in bone without overstuffing of the carrier or growth factor.

Abstract: Systems, methods, and carriers for percutaneous delivery of growth factors to treat osteonecrosis in the hip and other locations are disclosed. A rolled carrier comprising a biphasic ceramic rolled by a collagen sponge, and carrying a growth factor, are inserted via a delivery tube or cannula into a pre-formed hole in bone without overstuffing of the carrier or growth factor.

Abstract: Percutaneous implants are disclosed including a portion implantable into a patient, a dermal bonding region capable of forming a bond between the implant and a dermal layer of the patient after the implantable portion is implanted into the patient, and the dermal bonding region including a substrate with a discontinuous coating of particulate bioactive glass wherein the average spacing between the particles of bioactive glass is predetermined and at least about 20 microns prior to implantation into the patient. Also disclosed are bioactive coatings including a substrate and fibers and/or particles of bioactive glass distributed on the substrate with a predetermined average interfiber distance of at least about 20 microns.

Abstract: An improved implantable pharmaceutical depot for the prolonged release of at least one biologically active substance, the depot comprising a polymeric carrier and the biologically active substance, the improvement wherein the depot is coated or surface modified with a biologically active and biocompatible glass, glass-ceramic or ceramic material, the coating or modified surface being capable of forming a bond to soft tissue upon implantation. Methods for forming the biologically active and biocompatible glass, glass-ceramic or ceramic coating or modified surface on the silicone based depot are also disclosed.

Abstract: Percutaneous implants are disclosed including a portion implantable into a patient, a dermal bonding region capable of forming a bond between the implant and a dermal layer of the patient after the implantable portion is implanted into the patient, and the dermal bonding region including a substrate with a discontinuous coating of particulate bioactive glass wherein the average spacing between the particles of bioactive glass is predetermined and at least about 20 microns prior to implantation into the patient. Also disclosed are bioactive coatings including a substrate and fibers and/or particles of bioactive glass distributed on the substrate with a predetermined average interfiber distance of at least about 20 microns.